These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1829436)

  • 41. [Collagen diseases].
    Katsuta Y; Matsuo H
    Nihon Rinsho; 1970 Jul; 28(7):1880-5. PubMed ID: 5466525
    [No Abstract]   [Full Text] [Related]  

  • 42. [Our experiences with immunosuppressive therapy of rheumatic diseases].
    Malesević M; Andelić M; Nakicević M; Pasić I
    Med Arh; 1974 Jan; 28(0):suppl:65-9. PubMed ID: 4600455
    [No Abstract]   [Full Text] [Related]  

  • 43. [Current problems of immunology and immunosuppressive therapy in rheumatic diseases].
    Vorlaender KO
    Clin Ter; 1967 Jul; 42(1):3-14. PubMed ID: 4386113
    [No Abstract]   [Full Text] [Related]  

  • 44. Soluble interleukin 2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus.
    Raziuddin S; al-Janadi MA; al-Wabel AA
    J Rheumatol; 1991 Jun; 18(6):831-6. PubMed ID: 1680190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Value of the lymphocyte nucleolar parameters for the estimation of therapy effectiveness in chronic diseases with immune lymphocyte involvement.
    Micu D; Mihăilescu E; Sighetea E; Olinescu V; Constantineanu I
    Med Interne; 1979; 17(3):285-91. PubMed ID: 583079
    [No Abstract]   [Full Text] [Related]  

  • 46. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
    Ebo D; DeClerck LS; Bridts CH; Stevens WJ
    In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between CD29 density on CD8+ lymphocytes and serum IgG in systemic lupus erythematosus.
    Pallis M; Lim KL; Gardner-Medwin JM; Robins RA; Powell RJ
    Lupus; 1997; 6(4):379-84. PubMed ID: 9175023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunosuppressive therapy in rheumatic diseases. A retrospective study.
    Thomas MH; Bergen W; Philips VK; Rothermich NO
    Ohio State Med J; 1975 Sep; 71(11):624-6. PubMed ID: 1099500
    [No Abstract]   [Full Text] [Related]  

  • 49. [Current aspects of immunosuppressive therapy of collagen diseases].
    Marmont A; Rossi F; Bordo D
    Minerva Med; 1973 Jun; 64(46):2436-50. PubMed ID: 4723570
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapy of autoimmune nephropathy with steroids and cytostatics. A follow-up study of 80 patients and of 16 years.
    Petrányi G; Leövey A; Szegedi G; Kakuk G; Bobory J
    Acta Med Acad Sci Hung; 1971; 28(1):97-106. PubMed ID: 5133501
    [No Abstract]   [Full Text] [Related]  

  • 51. Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders.
    Nashel DJ
    Med Clin North Am; 1985 Jul; 69(4):817-40. PubMed ID: 3903379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
    Sharabi A; Azulai H; Sthoeger ZM; Mozes E
    Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
    Harten P
    Med Klin (Munich); 2003 Jun; 98(6):344; author reply 344-5. PubMed ID: 12877108
    [No Abstract]   [Full Text] [Related]  

  • 54. [Multicenter cooperative study of immunosuppressive therapy of systemic lupus erythematosus--a report of Therapy Research Division of Research Committee for Autoimmune Diseases, the Ministry of Health and Welfare].
    Ichikawa Y; Tanaka H; Hirose S; Yokohari R; Tsunematsu T
    Ryumachi; 1988 Aug; 28(4):230-9. PubMed ID: 3055347
    [No Abstract]   [Full Text] [Related]  

  • 55. [Immunosuppressive therapy with antineoplastic agents in rheumatoid arthritis].
    Fantini F; Cirla E; Tosi S; Solazzi F; Chériè Lignière G; Colombo B
    Reumatismo; 1970; 22(1):Suppl:96-117. PubMed ID: 5524874
    [No Abstract]   [Full Text] [Related]  

  • 56. Drug therapy: immunosuppressive agents (second of two parts).
    Kaplan SR; Calabresi P
    N Engl J Med; 1973 Dec; 289(23):1234-6. PubMed ID: 4594161
    [No Abstract]   [Full Text] [Related]  

  • 57. T cell subpopulations defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. II. Activated and functional subsets of helper-inducer and cytotoxic-suppressor subpopulations defined by two-colour fluorescence flow cytometry.
    Atkinson K
    Bone Marrow Transplant; 1986 Dec; 1(2):121-32. PubMed ID: 2971408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Micronucleus frequency in peripheral blood lymphocytes from patients with systemic lupus erythematosus.
    Severin E
    Rom J Morphol Embryol; 1995; 41(1-2):55-8. PubMed ID: 8680026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy.
    Rood MJ; Borggreve SE; Huizinga TW
    J Rheumatol; 2000 Aug; 27(8):2057-9. PubMed ID: 10955362
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immunosuppressive therapy of rheumatoid arthritis].
    Graudal H
    Ugeskr Laeger; 1971 Apr; 133(13):605-6. PubMed ID: 5554494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.